Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $61.5714.
A number of research analysts recently issued reports on the stock. Robert W. Baird raised their price objective on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the company an “outperform” rating in a report on Tuesday, September 9th. Raymond James Financial reiterated an “outperform” rating and issued a $63.00 price objective (up previously from $56.00) on shares of Dianthus Therapeutics in a report on Tuesday, September 9th. William Blair assumed coverage on shares of Dianthus Therapeutics in a report on Wednesday, July 2nd. They issued an “outperform” rating for the company. Guggenheim raised their price objective on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, September 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Saturday, September 27th.
Get Our Latest Stock Analysis on Dianthus Therapeutics
Dianthus Therapeutics Trading Down 5.4%
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.87 million. Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. As a group, equities analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.
Insider Transactions at Dianthus Therapeutics
In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total transaction of $700,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 8.15% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the company. Vestal Point Capital LP raised its holdings in Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after purchasing an additional 1,499,931 shares during the last quarter. RA Capital Management L.P. raised its holdings in Dianthus Therapeutics by 53.6% during the 1st quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company’s stock worth $52,003,000 after purchasing an additional 1,000,333 shares during the last quarter. Octagon Capital Advisors LP raised its holdings in Dianthus Therapeutics by 11.0% during the 1st quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company’s stock worth $42,478,000 after purchasing an additional 231,500 shares during the last quarter. Alliancebernstein L.P. grew its position in shares of Dianthus Therapeutics by 14.5% during the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock worth $21,887,000 after buying an additional 149,200 shares during the period. Finally, Candriam S.C.A. acquired a new stake in shares of Dianthus Therapeutics during the 1st quarter worth approximately $4,510,000. Institutional investors own 47.53% of the company’s stock.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Read More
- Five stocks we like better than Dianthus Therapeutics
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Why the Precious Metal Nobody Talks About Could Be Your Best Bet
- Investing in Commodities: What Are They? How to Invest in Them
- Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback
- Options Trading – Understanding Strike Price
- 3 Industrial Stocks Ready to Benefit From Fed Cuts and Spending
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.